Business Context and Reporting Period
Company: Dr. Reddy's Laboratories Limited (DRL)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Quarter and Nine Months ended December 31, 2008
Accounting Standard: International Financial Reporting Standards (IFRS) – First-time adoption period.
Business Overview: DRL is a leading India-based pharmaceutical company operating in three primary segments: Pharmaceutical Services and Active Ingredients (PSAI), Global Generics, and Proprietary Products. The company manufactures and markets generic drugs, active pharmaceutical ingredients (APIs), and proprietary products globally.
Key Financial Metrics
All figures in Indian Rupees (Rs.) in millions, unless otherwise noted. Convenience translation to U.S. dollars provided where applicable.
Income Statement Highlights (Nine Months Ended Dec 31, 2008)
| Metric | 2008 (9 Months) | 2007 (9 Months) |
|---|---|---|
| Revenue | Rs. 49,590 (U.S.$ 1,021) | Rs. 36,754 |
| Gross Profit | Rs. 25,731 | Rs. 18,385 |
| Gross Margin | 52% | 50% |
| Operating Profit | Rs. 6,635 | Rs. 1,126 |
| Net Profit (Profit for the period) | Rs. 4,609 (U.S.$ 95) | Rs. 2,911 |
| Basic EPS | Rs. 27.38 (U.S.$ 0.56) | Rs. 17.38 |
Balance Sheet Highlights (As of Dec 31, 2008)
| Metric | Dec 31, 2008 | Mar 31, 2008 |
|---|---|---|
| Total Assets | Rs. 96,341 (U.S.$ 1,983) | Rs. 84,827 |
| Cash and Cash Equivalents | Rs. 3,784 (U.S.$ 78) | Rs. 7,421 |
| Total Debt (Short + Long Term) | Rs. 21,163 (U.S.$ 435) | Rs. 18,917 |
| Total Equity | Rs. 51,850 (U.S.$ 1,067) | Rs. 47,350 |
Cash Flow (Nine Months Ended Dec 31, 2008)
- Operating Cash Flow: Net cash used of Rs. 678 million (U.S.$ 14 million). A significant decrease from the Rs. 3,467 million inflow in the prior year, driven by increased working capital requirements (inventory and receivables) and higher tax payments.
- Investing Cash Flow: Net cash used of Rs. 2,519 million (U.S.$ 52 million), primarily due to acquisitions and capital expenditures, partially offset by proceeds from the sale of investments.
- Financing Cash Flow: Net cash used of Rs. 955 million (U.S.$ 20 million), driven by debt repayments and dividends, partially offset by short-term borrowings.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 35% year-over-year for the nine months ended Dec 31, 2008. The Global Generics segment saw a 45% increase, driven by the launch of Sumatriptan (authorized generic of Imitrex) in the U.S. and acquisitions (Dow Pharma Unit, BASF Shreveport facility, Jet Generici).
- Profitability Surge: Net profit increased 58% to Rs. 4,609 million. This improvement is largely attributable to the absence of a Rs. 2,883 million write-down of intangible assets (betapharm) that occurred in the same period of 2007.
- Foreign Exchange Impact: The Indian Rupee depreciated significantly against the U.S. Dollar (approx. 24% for the quarter). While this increased rupee realization from U.S. sales, it resulted in mark-to-market losses on foreign currency derivatives and translation losses on foreign currency debt.
- Acquisitions: The company completed several strategic acquisitions in April 2008, including units of Dow Chemical (UK), BASF (USA), and Jet Generici (Italy), which contributed to revenue growth.
Guidance, Outlook, Risks, and Unusual Items
Unusual Items and Contingencies
- Olanzapine Litigation (Germany): In December 2008, the German Federal Court of Justice upheld Eli Lilly's patent for olanzapine. DRL ceased marketing the product in Germany and recorded a provision of Rs. 224.4 million for the quarter ended Dec 31, 2008 (part of a total estimated loss of Rs. 969 million for the nine months) for probable damages. This is a significant contingent liability.
- German Tender Process: Results of a competitive bidding process (tender) with AOK (a major German health insurer) were put on hold due to litigation by drug manufacturers. This creates uncertainty regarding DRL's market share in Germany.
- FTC Investigation: The U.S. Federal Trade Commission (FTC) is conducting a civil antitrust investigation regarding DRL's settlement with UCB Pharma concerning levetiracetam. The investigation remains open, though no further information requests have been made recently.
Management Commentary and Outlook
- U.S. Market: Strong growth expected from the Sumatriptan launch and the Shreveport facility. The company aims to expand its over-the-counter and government business channels.
- Germany: Continued pressure on prices due to healthcare reforms. Management is shifting sourcing to internal networks to reduce costs and supply risks.
- Proprietary Products: Launched Promius Pharma in the U.S. to focus on dermatology products (e.g., EpiCeram, Scytera). This is a strategic move to build a branded business, though not expected to be a major financial contributor immediately.
- IFRS Transition: The company is in its first year of reporting under IFRS. Comparisons with prior periods are affected by accounting policy changes, particularly regarding impairment testing, employee benefits, and hedge accounting.
Investor Verification Checklist
- Olanzapine Liability: Verify the final settlement amount or court judgment regarding the Eli Lilly patent infringement in Germany, as the current provision is an estimate.
- German Tender Outcome: Monitor the resolution of the AOK tender litigation to assess potential market share loss in the German generics market.
- FTC Investigation Status: Track the status of the FTC antitrust investigation regarding the UCB Pharma settlement to ensure no fines or penalties are imposed.
- Foreign Exchange Exposure: Assess the company's hedging strategy effectiveness given the volatility of the INR/USD exchange rate and its impact on reported earnings.
- Sumatriptan Sustainability: Evaluate the long-term revenue contribution of the Sumatriptan launch, as it significantly boosted Q3/Q4 2008 results.
- Working Capital Trends: Review the trend in receivables and inventory levels, as the shift to negative operating cash flow was driven by increased working capital needs.